# KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer

> **NCT02205463** · PHASE1 · WITHDRAWN · sponsor: **NYU Langone Health**

## Conditions studied

- Esophageal Cancer
- Stomach Cancer

## Interventions

- **DRUG:** KD019

## Key facts

- **NCT ID:** NCT02205463
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-12
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** IND application withdrawn
- **Last updated:** 2014-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02205463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02205463, "KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02205463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*